- Home
- NVCT vs INMD Comparison
NVCT vs INMD Comparison
Compare NVCT & INMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NVCT | INMD |
|---|---|---|
| Founded | 2020 | 2008 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 721.2M | 842.0M |
| IPO Year | 2021 | 2018 |
Fundamental Metrics
Financial Performance| Metric | NVCT | INMD |
|---|---|---|
| Price | $19.08 | $15.36 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 5 |
| Target Price | $10.00 | ★ $17.33 |
| AVG Volume (30 Days) | 589.5K | ★ 827.0K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1.74 |
| Revenue Next Year | N/A | $3.26 |
| P/E Ratio | ★ N/A | $10.11 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.55 | $12.72 |
| 52 Week High | $29.28 | $16.74 |
Technical Indicators
Market Signals| Indicator | NVCT | INMD |
|---|---|---|
| Relative Strength Index (RSI) | 54.68 | 63.09 |
| Support Level | $18.02 | $13.27 |
| Resistance Level | $29.28 | $15.72 |
| Average True Range (ATR) | 1.26 | 0.31 |
| MACD | -0.50 | 0.04 |
| Stochastic Oscillator | 38.24 | 73.62 |
Price Performance
Historical ComparisonAbout NVCT Nuvectis Pharma Inc.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
About INMD InMode Ltd.
InMode Ltd provides minimally and non-invasive surgical aesthetic and medical treatment solutions. Its products and solutions address three energy-based treatment categories that include face & body contouring, medical aesthetics, and women's health. InMode has developed products using its technology for plastic surgery, dermatology, gynecology, and ophthalmology. Its product platforms include BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF, and Morpheus8, among others. Geographically, the company generates the majority of its revenue from the United States, followed by Europe, Asia, Israel, and other regions.